1584 related articles for article (PubMed ID: 21831711)
1. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
2. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
3. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
4. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Di Stasi SM; Giannantoni A; Giurioli A; Valenti M; Zampa G; Storti L; Attisani F; De Carolis A; Capelli G; Vespasiani G; Stephen RL
Lancet Oncol; 2006 Jan; 7(1):43-51. PubMed ID: 16389183
[TBL] [Abstract][Full Text] [Related]
5. [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
Rehme C; Niedworok C; Rübben H; Vom Dorp F
Urologe A; 2015 Feb; 54(2):235-8. PubMed ID: 25316185
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
7. [Intravesical therapy with mitomycin through electromotive drug administration].
Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
[TBL] [Abstract][Full Text] [Related]
9. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
10. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Liberati E; Dutto L; Verri C
Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
Onishi T; Sugino Y; Shibahara T; Masui S; Yabana T; Sasaki T
BJU Int; 2017 Feb; 119(2):276-282. PubMed ID: 27444991
[TBL] [Abstract][Full Text] [Related]
13. The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial.
El Azab A; Abdelbary A; El Faqeh M Okasha A; Aboulkassem H; Saad Zaghloul A; Mohamed Karkeet R; Abdelrahman I
Investig Clin Urol; 2023 Nov; 64(6):554-560. PubMed ID: 37932566
[TBL] [Abstract][Full Text] [Related]
14. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
15. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
16. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Riedl C
World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
[TBL] [Abstract][Full Text] [Related]
17. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Mostafid AH; Rajkumar RG; Stewart AB; Singh R
BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
[TBL] [Abstract][Full Text] [Related]
18. The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.
Bosschieter J; van Moorselaar RJA; Vis AN; van Ginkel T; Lissenberg-Witte BI; Beckers GMA; Nieuwenhuijzen JA
BJU Int; 2018 Oct; 122(4):571-575. PubMed ID: 29319922
[TBL] [Abstract][Full Text] [Related]
19. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
[TBL] [Abstract][Full Text] [Related]
20. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
